Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 ( SGLT2 ) inhibitor, in subjects with renal impairment
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Aims: Empagliflozin is a selective sodium glucose cotransporter 2 ( SGLT2 ) inhibitor that inhibits renal glucose reabsorption and is being investigated for the treatment of type 2 diabetes mellitus ( T2DM ). Methods: In this open‐label study, the effect of renal impairment on the pharmacokinetics, pharmacodynamics and safety of a 50 mg dose of empagliflozin was investigated in 40 subjects, grouped according to estimated glomerular filtration rate ( eGFR ). Results: Maximum empagliflozin plasma concentrations were similar in subjects with normal renal function and renal impairment. Area under the empagliflozin concentration‐time curve ( AUC 0 –∞ ) values increased by approximately 18, 20, 66 and 48% in subjects with mild, moderate, severe renal impairment and renal failure/end stage renal disease ( ESRD ), respectively, in comparison to healthy subjects. This was attributed to decreased renal clearance ( CL R ). Urinary glucose excretion ( UGE ) decreased with increasing renal impairment and correlated with decreased eGFR and CL R . Empagliflozin was well tolerated, with no increase in adverse events associated with renal impairment. Conclusions: Renal insufficiency resulted in decreased CL R of empagliflozin, moderately increased systemic exposure and decreased UGE . A single 50 mg dose of empagliflozin was well tolerated in subjects with normal renal function and any degree of renal impairment. The pharmacokinetic results of this study indicate that no dose adjustment of empagliflozin is required in patients with renal impairment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grempler, R., Thomas, L., Eckhardt, M., Himmelsbach, F., Sauer, A., Sharp, D. E., Bakker, R. A., Mark, M., Klein, T., & Eickelmann, P. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01517.x · Cited by 608
Cited by
Baigent, C., Emberson, J., Haynes, R., Herrington, W. G., Judge, P., Landray, M. J., Mayne, K. J., Ng, S. Y. A., Preiss, D., Roddick, A. J., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)02074-8 · Cited by 1,020
“…a wide range of kidney function have been studied in the reported trials, and despite attenuation of the effects of SGLT2 inhibitors on glycosuria with lower kidney function, (46) there was no suggestion kidney benefits were attenuated when trials were ordered by average baseline kidney function.”
Barnett, A. H., Mithal, A., Manassie, J., Jones, R., Rattunde, H., Woerle, H. J., & Broedl, U. C. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70208-0 · Cited by 574
Self-citationScheen, A. J. (2015) · Drugs · doi:10.1007/s40265-014-0337-y · Cited by 554
Wanner, C., Lachin, J. M., Inzucchi, S. E., Fitchett, D., Mattheus, M., George, J., Woerle, H. J., Broedl, U. C., von Eynatten, M., & Zinman, B. (2018) · Circulation · doi:10.1161/circulationaha.117.028268 · Cited by 469
Self-citationVrhovac, I., Balen Eror, D., Klessen, D., Burger, C., Breljak, D., Kraus, O., Radović, N., Jadrijević, S., Aleksic, I., Walles, T., et al. (2015) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-014-1619-7 · Cited by 290
Byrne, N. J., Matsumura, N., Maayah, Z. H., Ferdaoussi, M., Takahara, S., Darwesh, A. M., Levasseur, J. L., Jahng, J. W. S., Vos, D., Parajuli, N., et al. (2020) · Circulation: Heart Failure · doi:10.1161/circheartfailure.119.006277 · Cited by 257
Cherney, D. Z. I., Cooper, M. E., Tikkanen, I., Pfarr, E., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Lund, S. S. (2018) · Kidney International · doi:10.1016/j.kint.2017.06.017 · Cited by 243
Self-citationSGLT2 inhibition: efficacy and safety in type 2 diabetes treatment
Scheen, A. J. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1100167 · Cited by 70
“[115,116] Notably, PD changes are critically dependent on renal function and urinary glucose excretion progressively decreases with the degree of renal impairment, leading to a progressive attenuation of the glucose-lowering effects in T2DM patients.[113,114,117] Nevertheless, despite the reduction in urinary glucose…”
Background
Metadata
- Authors
- Macha, S., Mattheus, M., Halabi, A., Pinnetti, S., Woerle, H. J., & Broedl, U. C.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2013-08-19
- Volume
- 16
- Issue
- 3
- Pages
- 215-222
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W1994679938
- Cited by
- 113
- References
- 2
- FWCI
- 9.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.